18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.

UNLABELLED Recent reports have indicated the value and limitations of (18)F-FDG PET and (201)Tl SPECT for determination of malignancy. We prospectively assessed and compared the usefulness of these scintigraphic examinations as well as (18)F-FDG PET delayed imaging for the evaluation of thoracic abnormalities. METHODS Eighty patients with thoracic nodular lesions seen on chest CT images were examined using early and delayed (18)F-FDG PET and (201)Tl-SPECT imaging within 1 wk of each study. The results of (18)F-FDG PET and (201)Tl SPECT were evaluated and compared with the histopathologic diagnosis. RESULTS Fifty of the lesions were histologically confirmed to be malignant, whereas 30 were benign. On (18)F-FDG PET, all malignant lesions showed higher standardized uptake value (SUV) levels at 3 than at 1 h, and benign lesions revealed the opposite results. Correlations were seen between (18)F-FDG PET imaging and the degree of cell differentiation in malignant tumors. No significant difference in accuracy was found between (18)F-FDG PET single-time-point imaging and (201)Tl SPECT for the differentiation of malignant and benign thoracic lesions. However, the retention index (RI) of (18)F-FDG PET (RI-SUV) significantly improved the accuracy of thoracic lesion diagnosis. Furthermore, (18)F-FDG PET delayed imaging measuring RI-SUV metastasis was useful for diagnosing nodal involvement and it improved the specificity of mediastinal staging. CONCLUSION No significant difference was found between (18)F-FDG PET single-time-point imaging and (201)Tl SPECT for the differentiation of malignant and benign thoracic lesions. The RI calculated by (18)F-FDG PET delayed imaging provided more accurate diagnoses of lung cancer.

[1]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Binns,et al.  Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible , 2001, Medical Journal of Australia.

[4]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[5]  P. Lewis,et al.  Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Coleman,et al.  PET in lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[8]  I. Leav,et al.  The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. , 1996, Nuclear medicine and biology.

[9]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  S. Larson Cancer or inflammation? A Holy Grail for nuclear medicine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Luketich,et al.  Fluorine-18-fluorodeoxyglucose uptake in pneumonia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Mandelkern,et al.  Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. , 1996, American journal of respiratory and critical care medicine.

[13]  M D Blaufox,et al.  PET imaging in oncology. , 2000, Seminars in nuclear medicine.

[14]  R L Wahl,et al.  Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  K. Mori,et al.  Mediastinal lymph node metastasis from lung cancer: evaluation with Tl-201 SPECT--comparison with CT. , 1994, Radiology.

[16]  H. Tonami,et al.  Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Herzog,et al.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer , 1999, European Journal of Nuclear Medicine.

[18]  A. Alavi,et al.  Thallium-201 uptake in lung cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  S. Suzuki,et al.  Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. , 1984, Archives of biochemistry and biophysics.

[21]  J. Goo,et al.  Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. , 2000, Radiology.

[22]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[23]  J. Ruhlmann,et al.  PET in Oncology , 1999, Springer Berlin Heidelberg.

[24]  E. Nitzsche,et al.  Evaluation of positron emission tomography with 2‐[18F]fluoro‐2‐deoxy‐D‐glucose for the differentiation of chronic pancreatitis and pancreatic cancer , 1999, The British journal of surgery.

[25]  M. Schwaiger,et al.  Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules , 1998, The British journal of surgery.

[26]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Y. Kawakami,et al.  Thallium-201 uptake, histopathological differentiation and Na-K ATPase in lung adenocarcinoma. , 1996, Journal of Nuclear Medicine.

[28]  Hiroshi Fukuda,et al.  Advantage of delayed whole-body FDG-PET imaging for tumour detection , 2001, European Journal of Nuclear Medicine.

[29]  N. Gupta,et al.  Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. , 1998, Chest.

[30]  S. Reske,et al.  How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? , 2000, The thoracic and cardiovascular surgeon.

[31]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  R Iwata,et al.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.